Importance: More than half of all new melanoma diagnoses present as clinically localized T1 melanoma, yet sentinel lymph node biopsy (SLNB) is controversial in this population given the overall low yield. Guidelines for SLNB have focused on pathologic factors, but patient factors, such as age, are not routinely considered. Objectives: To identify indicators of lymph node (LN) metastasis in thin melanoma in a large, generalizable data set and to evaluate the association between patient age and LN positivity. Design, Setting, and Participants: A retrospective cohort study using the National Cancer Database, an oncology database representing patients from more than 1500 hospitals throughout the United States, was performed (2010-2013). Data analysis was conducted from October 1, 2016, to January 15, 2017. A total of 8772 patients with clinical stage I 0.50 to 1.0 mm thin melanoma undergoing wide excision and surgical evaluation of regional LNs were included for study. Main Outcome and Measures: The primary outcome of interest was presence of melanoma in a biopsied regional LN. Clinicopathologic factors associated with LN positivity were characterized, using logistic regression. Age was categorized as younger than 40 years, 40 to 64 years, and 65 years or older for multivariable analysis. Classification tree analysis was performed to identify high-risk groups for LN positivity. Results: Among the study cohort (n = 8772), 333 patients had nodal metastases, for an overall positivity rate of 3.8% (95% CI, 3.4%-4.2%). A total of 4087 (54.0%) patients were women. Median age was 56 years (interquartile range [IQR], 46-67) in patients with negative LNs and 52 years (IQR, 41-61) in those with positive LNs (P < .001). In multivariable analysis, younger age, female sex, thickness of 0.76 mm or larger, increasing Clark level, mitoses, ulceration, and lymphovascular invasion were independently associated with LN positivity. In decision tree analysis, patient age was identified as an important risk stratifier for LN metastases, after mitoses and thickness. Patients younger than 40 years with category T1b tumors 0.50 to 0.75 mm, who would generally not be recommended for SLNB, had an LN positivity rate of 5.6% (95% CI, 3.3%-8.6%); conversely, patients 65 years or older with T1b tumors 0.76 mm or larger, who would generally be recommended for SLNB, had an LN positivity rate of only 3.9% (95% CI, 2.7%-5.3%). Conclusions and Relevance: Patient age is an important factor in estimating lymph node positivity in thin melanoma independent of traditional pathologic factors. Age therefore should be taken into consideration when selecting patients for nodal biopsy.
Importance: More than half of all new melanoma diagnoses present as clinically localized T1 melanoma, yet sentinel lymph node biopsy (SLNB) is controversial in this population given the overall low yield. Guidelines for SLNB have focused on pathologic factors, but patient factors, such as age, are not routinely considered. Objectives: To identify indicators of lymph node (LN) metastasis in thin melanoma in a large, generalizable data set and to evaluate the association between patient age and LN positivity. Design, Setting, and Participants: A retrospective cohort study using the National Cancer Database, an oncology database representing patients from more than 1500 hospitals throughout the United States, was performed (2010-2013). Data analysis was conducted from October 1, 2016, to January 15, 2017. A total of 8772 patients with clinical stage I 0.50 to 1.0 mm thin melanoma undergoing wide excision and surgical evaluation of regional LNs were included for study. Main Outcome and Measures: The primary outcome of interest was presence of melanoma in a biopsied regional LN. Clinicopathologic factors associated with LN positivity were characterized, using logistic regression. Age was categorized as younger than 40 years, 40 to 64 years, and 65 years or older for multivariable analysis. Classification tree analysis was performed to identify high-risk groups for LN positivity. Results: Among the study cohort (n = 8772), 333 patients had nodal metastases, for an overall positivity rate of 3.8% (95% CI, 3.4%-4.2%). A total of 4087 (54.0%) patients were women. Median age was 56 years (interquartile range [IQR], 46-67) in patients with negative LNs and 52 years (IQR, 41-61) in those with positive LNs (P < .001). In multivariable analysis, younger age, female sex, thickness of 0.76 mm or larger, increasing Clark level, mitoses, ulceration, and lymphovascular invasion were independently associated with LN positivity. In decision tree analysis, patient age was identified as an important risk stratifier for LN metastases, after mitoses and thickness. Patients younger than 40 years with category T1b tumors 0.50 to 0.75 mm, who would generally not be recommended for SLNB, had an LN positivity rate of 5.6% (95% CI, 3.3%-8.6%); conversely, patients 65 years or older with T1b tumors 0.76 mm or larger, who would generally be recommended for SLNB, had an LN positivity rate of only 3.9% (95% CI, 2.7%-5.3%). Conclusions and Relevance: Patient age is an important factor in estimating lymph node positivity in thin melanoma independent of traditional pathologic factors. Age therefore should be taken into consideration when selecting patients for nodal biopsy.
Authors: R S Oliveira Filho; L M Ferreira; L J Biasi; M M S S Enokihara; G R Paiva; J Wagner Journal: Braz J Med Biol Res Date: 2003-03-07 Impact factor: 2.590
Authors: Karyn B Stitzenberg; Pamela A Groben; Stacey L Stern; Nancy E Thomas; Thomas A Hensing; Leah B Sansbury; David W Ollila Journal: Ann Surg Oncol Date: 2004-09-20 Impact factor: 5.344
Authors: Dale Han; Jonathan S Zager; Yu Shyr; Heidi Chen; Lynne D Berry; Sanjana Iyengar; Mia Djulbegovic; Jaimie L Weber; Suroosh S Marzban; Vernon K Sondak; Jane L Messina; John T Vetto; Richard L White; Barbara Pockaj; Nicola Mozzillo; Kim James Charney; Eli Avisar; Robert Krouse; Mohammed Kashani-Sabet; Stanley P Leong Journal: J Clin Oncol Date: 2013-11-04 Impact factor: 44.544
Authors: Andrea Maurichi; Rosalba Miceli; Tiziana Camerini; Luigi Mariani; Roberto Patuzzo; Roberta Ruggeri; Gianfranco Gallino; Elena Tolomio; Gabrina Tragni; Barbara Valeri; Andrea Anichini; Roberta Mortarini; Daniele Moglia; Giovanni Pellacani; Sara Bassoli; Caterina Longo; Pietro Quaglino; Nicola Pimpinelli; Lorenzo Borgognoni; Daniele Bergamaschi; Catherine Harwood; Odysseas Zoras; Mario Santinami Journal: J Clin Oncol Date: 2014-07-07 Impact factor: 44.544
Authors: M Mandalà; G L Imberti; D Piazzalunga; M Belfiglio; R Labianca; M Barberis; L Marchesi; P Poletti; L Bonomi; L Novellino; K Di Biagio; A Milesi; U Guerra; C Tondini Journal: Eur J Cancer Date: 2009-06-22 Impact factor: 9.162
Authors: Richard J B Walker; Nicole J Look Hong; Marc Moncrieff; Alexander C J van Akkooi; Evan Jost; Carolyn Nessim; Winan J van Houdt; Emma H A Stahlie; Chanhee Seo; May Lynn Quan; J Gregory McKinnon; Frances C Wright; Michail N Mavros Journal: Ann Surg Oncol Date: 2022-06-08 Impact factor: 4.339
Authors: Antonio Tejera-Vaquerizo; Simone Ribero; Susana Puig; Aram Boada; Sabela Paradela; David Moreno-Ramírez; Javier Cañueto; Blanca de Unamuno; Ana Brinca; Miguel A Descalzo-Gallego; Simona Osella-Abate; Paola Cassoni; Cristina Carrera; Sergi Vidal-Sicart; Antoni Bennássar; Ramón Rull; Llucìa Alos; Celia Requena; Isidro Bolumar; Víctor Traves; Ángel Pla; A Fernández-Orland; Ane Jaka; María T Fernández-Figueres; Josep M Hilari; Pol Giménez-Xavier; Ricardo Vieira; Rafael Botella-Estrada; Concepción Román-Curto; Lara Ferrándiz; Nicolás Iglesias-Pena; Carlos Ferrándiz; Josep Malvehy; Pietro Quaglino; Eduardo Nagore Journal: Cancer Med Date: 2019-06-18 Impact factor: 4.452
Authors: Alexandra S Berghe; Gheorghe Cobzac; George Dindelegan; Simona C Șenilă; Corina I Baican; Carolina M Solomon; Liliana Rogojan; Daniel C Leucuța; Tudor C Drugan; Sorana D Bolboacă Journal: Exp Ther Med Date: 2021-05-05 Impact factor: 2.447
Authors: Taylor J Aiken; David Komjathy; Matthew Rodriguez; Ashley Stuckwisch; Arika Feils; Vladimir Subbotin; Jen Birstler; Stephen D Gillies; Alexander L Rakhmilevich; Amy K Erbe; Paul M Sondel Journal: J Immunother Cancer Date: 2022-01 Impact factor: 13.751
Authors: Antonio G Richetta; Virginia Valentini; Federica Marraffa; Giovanni Paolino; Piera Rizzolo; Valentina Silvestri; Veronica Zelli; Anna Carbone; Cinzia Di Mattia; Stefano Calvieri; Pasquale Frascione; Pietro Donati; Laura Ottini Journal: Oncotarget Date: 2018-08-14
Authors: Eric D Whitman; Vadim P Koshenkov; Brian R Gastman; Deri Lewis; Eddy C Hsueh; Ho Pak; Thomas P Trezona; Robert S Davidson; Michael McPhee; J Michael Guenther; Paul Toomey; Franz O Smith; Peter D Beitsch; James M Lewis; Andrew Ward; Shawn E Young; Parth K Shah; Ann P Quick; Brian J Martin; Olga Zolochevska; Kyle R Covington; Federico A Monzon; Matthew S Goldberg; Robert W Cook; Martin D Fleming; David M Hyams; John T Vetto Journal: JCO Precis Oncol Date: 2021-09-13